small molecule

LAZCLUZE

LAZERTINIB MESYLATE

Loss of exclusivityAugust 2041latest FDA-listed patent expiry

CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand name	LAZCLUZE
Active ingredient	LAZERTINIB MESYLATE
Strength	EQ 240MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	August 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11850248	August 2041	use U-3985
12138351	April 2041	product
11879013	May 2040	use U-3985
12599606	May 2040	use U-4511
12318390	April 2038	product
11453656	April 2038	substance, product
11981659	April 2038	use U-3985
9593098	October 2035	substance, product

Regulatory exclusivity

Code	Expires
NCE	August 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Janssen Biotech